Prognostic assessment in COPD without lung function: the B-AE-D indices.

Area of Science:

• Pulmonary Medicine
• Clinical Risk Assessment
• Biomarker Discovery

Background:

• Existing composite markers for COPD risk assessment often have complex parameters, limiting clinical use.
• Lung function is a key parameter in many COPD risk indices, but it is not always readily available.

Purpose of the Study:

• To develop and validate a simplified COPD risk index that is independent of lung function.
• To assess the performance of the novel index in predicting COPD-related and all-cause mortality.

Main Methods:

• A novel prognostic index was developed using the PROMISE study (n=530).
• The index was validated in external cohorts (ProCOLD, COCOMICS, COMIC; n=2988) for predicting mortality.
• The B-AE-D index (Body mass index, severe Acute Exacerbations, Dyspnea) and B-AE-D-C (including copeptin) were evaluated.

Main Results:

• The B-AE-D and B-AE-D-C indices demonstrated comparable or superior performance to existing indices (BODE, ADO, DOSE) in predicting 2-year all-cause mortality.
• Both novel indices showed high accuracy in predicting 2-year COPD-related mortality (c-statistics: 0.87 and 0.89).
• External validation confirmed the predictive ability of the B-AE-D index for all-cause mortality.

Conclusions:

• The B-AE-D index offers a simple yet accurate method for assessing COPD risk.
• Incorporating copeptin (B-AE-D-C) can further improve risk stratification when available.
• This lung function-independent index enhances clinical applicability for COPD risk assessment.